Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Return on Sales: 2020-2025

Historic Return on Sales for Whitehawk Therapeutics (WHWK) over the last 4 years, with Mar 2025 value amounting to -2.15%.

  • Whitehawk Therapeutics' Return on Sales rose 62.00% to -2.15% in Q1 2025 from the same period last year, while for Mar 2025 it was -2.15%, marking a year-over-year increase of 62.00%. This contributed to the annual value of -2.45% for FY2024, which is 25.00% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Return on Sales of -2.15% as of Q1 2025, which was up 12.12% from -2.45% recorded in Q4 2024.
  • In the past 5 years, Whitehawk Therapeutics' Return on Sales registered a high of -0.13% during Q2 2021, and its lowest value of -8.01% during Q4 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Return on Sales value was -2.61% (recorded in 2023), while the average stood at -2.65%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by 791bps in 2021, then surged by 417bps in 2023.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Return on Sales stood at -8.01% in 2021, then spiked by 404bps to -3.98% in 2022, then surged by 139bps to -2.59% in 2023, then increased by 14bps to -2.45% in 2024, then surged by 62bps to -2.15% in 2025.
  • Its last three reported values are -2.15% in Q1 2025, -2.45% for Q4 2024, and -2.46% during Q3 2024.